Circulating tumor cells

From bench to bedside

Marija Balic, Anthony Williams, Henry Lin, Ram Datar, Richard J Cote

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Circulating tumor cells (CTCs) represent a surrogate biomarker of hematogenous metastases. In recent years, their detection has gained increasing interest. There is ample evidence regarding the ability to detect CTCsand their prognostic relevance, but their demonstrated predictive value in therapeutic response monitoring is clinically even more meaningful. Many clinical trials in the early and metastatic cancer setting now include CTCs as a monitoring parameter, and numerous translational studies attempting their molecular characterization are under way. There has been great progress in defining the clinical importance of CTCs, and it now seems likely that we may expect wider implementation of CTCs as a diagnostic oncology tool to monitor therapeutic response in real time. Novel technologies may further facilitate molecular characterization of CTCs and development of novel therapeutic targets, possibly leading to more powerful treatment strategies for cancer patients. As the detection and evaluation of CTCs are becoming an increasingly important diagnostic and prognostic tool, the goal of this review is to communicate the knowledge obtained through analysis of primary tumors and CTCs to oncologists and medical specialists in managing patients with cancer.

Original languageEnglish
Pages (from-to)31-44
Number of pages14
JournalAnnual Review of Medicine
Volume64
DOIs
StatePublished - Jan 14 2013

Fingerprint

Circulating Neoplastic Cells
Tumors
Cells
Neoplasms
Therapeutics
Oncology
Monitoring
Biomarkers
Clinical Trials
Neoplasm Metastasis
Technology

Keywords

  • cancer stem cells (CSCs)
  • disseminated tumor cells (DTCs)
  • micrometastasis
  • minimal residual disease
  • therapeutic response

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Circulating tumor cells : From bench to bedside. / Balic, Marija; Williams, Anthony; Lin, Henry; Datar, Ram; Cote, Richard J.

In: Annual Review of Medicine, Vol. 64, 14.01.2013, p. 31-44.

Research output: Contribution to journalArticle

Balic, Marija ; Williams, Anthony ; Lin, Henry ; Datar, Ram ; Cote, Richard J. / Circulating tumor cells : From bench to bedside. In: Annual Review of Medicine. 2013 ; Vol. 64. pp. 31-44.
@article{d54f0d15e2a444108bc98f0050c3961d,
title = "Circulating tumor cells: From bench to bedside",
abstract = "Circulating tumor cells (CTCs) represent a surrogate biomarker of hematogenous metastases. In recent years, their detection has gained increasing interest. There is ample evidence regarding the ability to detect CTCsand their prognostic relevance, but their demonstrated predictive value in therapeutic response monitoring is clinically even more meaningful. Many clinical trials in the early and metastatic cancer setting now include CTCs as a monitoring parameter, and numerous translational studies attempting their molecular characterization are under way. There has been great progress in defining the clinical importance of CTCs, and it now seems likely that we may expect wider implementation of CTCs as a diagnostic oncology tool to monitor therapeutic response in real time. Novel technologies may further facilitate molecular characterization of CTCs and development of novel therapeutic targets, possibly leading to more powerful treatment strategies for cancer patients. As the detection and evaluation of CTCs are becoming an increasingly important diagnostic and prognostic tool, the goal of this review is to communicate the knowledge obtained through analysis of primary tumors and CTCs to oncologists and medical specialists in managing patients with cancer.",
keywords = "cancer stem cells (CSCs), disseminated tumor cells (DTCs), micrometastasis, minimal residual disease, therapeutic response",
author = "Marija Balic and Anthony Williams and Henry Lin and Ram Datar and Cote, {Richard J}",
year = "2013",
month = "1",
day = "14",
doi = "10.1146/annurev-med-050311-163404",
language = "English",
volume = "64",
pages = "31--44",
journal = "Annual Review of Medicine",
issn = "0066-4219",
publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - Circulating tumor cells

T2 - From bench to bedside

AU - Balic, Marija

AU - Williams, Anthony

AU - Lin, Henry

AU - Datar, Ram

AU - Cote, Richard J

PY - 2013/1/14

Y1 - 2013/1/14

N2 - Circulating tumor cells (CTCs) represent a surrogate biomarker of hematogenous metastases. In recent years, their detection has gained increasing interest. There is ample evidence regarding the ability to detect CTCsand their prognostic relevance, but their demonstrated predictive value in therapeutic response monitoring is clinically even more meaningful. Many clinical trials in the early and metastatic cancer setting now include CTCs as a monitoring parameter, and numerous translational studies attempting their molecular characterization are under way. There has been great progress in defining the clinical importance of CTCs, and it now seems likely that we may expect wider implementation of CTCs as a diagnostic oncology tool to monitor therapeutic response in real time. Novel technologies may further facilitate molecular characterization of CTCs and development of novel therapeutic targets, possibly leading to more powerful treatment strategies for cancer patients. As the detection and evaluation of CTCs are becoming an increasingly important diagnostic and prognostic tool, the goal of this review is to communicate the knowledge obtained through analysis of primary tumors and CTCs to oncologists and medical specialists in managing patients with cancer.

AB - Circulating tumor cells (CTCs) represent a surrogate biomarker of hematogenous metastases. In recent years, their detection has gained increasing interest. There is ample evidence regarding the ability to detect CTCsand their prognostic relevance, but their demonstrated predictive value in therapeutic response monitoring is clinically even more meaningful. Many clinical trials in the early and metastatic cancer setting now include CTCs as a monitoring parameter, and numerous translational studies attempting their molecular characterization are under way. There has been great progress in defining the clinical importance of CTCs, and it now seems likely that we may expect wider implementation of CTCs as a diagnostic oncology tool to monitor therapeutic response in real time. Novel technologies may further facilitate molecular characterization of CTCs and development of novel therapeutic targets, possibly leading to more powerful treatment strategies for cancer patients. As the detection and evaluation of CTCs are becoming an increasingly important diagnostic and prognostic tool, the goal of this review is to communicate the knowledge obtained through analysis of primary tumors and CTCs to oncologists and medical specialists in managing patients with cancer.

KW - cancer stem cells (CSCs)

KW - disseminated tumor cells (DTCs)

KW - micrometastasis

KW - minimal residual disease

KW - therapeutic response

UR - http://www.scopus.com/inward/record.url?scp=84873028083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873028083&partnerID=8YFLogxK

U2 - 10.1146/annurev-med-050311-163404

DO - 10.1146/annurev-med-050311-163404

M3 - Article

VL - 64

SP - 31

EP - 44

JO - Annual Review of Medicine

JF - Annual Review of Medicine

SN - 0066-4219

ER -